COMMUNIQUÉS West-GlobeNewswire

IBA’s joint venture PanTera secures EUR 93 million in oversubscribed Series A round to accelerate global actinium-225 production

11/09/2024 - 07:00

Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture PanTera, which is [...]

PanTera, la joint-venture d’IBA, obtient 93 millions d'euros lors d'une levée de fonds de série A sursouscrite pour accélérer la production mondiale d'actinium-225

11/09/2024 - 07:00

Louvain-La-Neuve, Belgique, le 11 septembre 2024 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’accélération de particules, partage aujourd’hui le communiqué de presse ci-dessous concernant sa [...]

Bioversys Announces Strategic Investment From GIBF2 and Launch of BV100 Clinical Program in China

11/09/2024 - 07:00

BASEL, Switzerland, Sept. 11, 2024 (GLOBE NEWSWIRE) -- GIBF2 to invest US$ 6m in BioVersys BV100 Phase 1 study in China expected to start in 1H 2025 in preparation for a global Phase 3 registrational study BioVersys AG [...]

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

11/09/2024 - 07:00

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary endpoints in adults [...]

Communiqué de presse : Dupixent est le premier et le seul agent biologique à obtenir des améliorations significatives de la rémission de la maladie et des symptômes dans l’étude pivot sur des patients atteints de pemphigoïde bulleuse

11/09/2024 - 07:00

Dupixent est le premier et le seul agent biologique à obtenir des améliorations significatives de la rémission de la maladie et des symptômes dans l’étude pivot sur des patients atteints de pemphigoïde bulleuse L’étude [...]

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

11/09/2024 - 06:59

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is the first medicine to [...]

Terns Announces Pricing of Upsized $150.15 Million Public Offering

11/09/2024 - 04:50

FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

11/09/2024 - 02:21

CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]

‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology

11/09/2024 - 00:38

MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON 1 trial have been published in The [...]

Prophylactic dexamethasone regimen reduces infusion-related reactions in patients with EGFR-mutated advanced non-small cell lung cancer treated with intravenous RYBREVANT®▼ (amivantamab)

11/09/2024 - 00:20

The 8 mg pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous amivantamab, a three-fold reduction from 67.4 percent historically seen with standard IRR management 1 ,2 BEERSE [...]

Sienna Announces Offering of $150 Million Aggregate Principal Amount of 4.436% Series D Senior Unsecured Debentures

10/09/2024 - 23:33

NOT FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MARKHAM, Ontario, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) [...]

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

10/09/2024 - 22:45

- Increase in endogenous cortisol production achieved in all patients in higher dose cohorts of BBP-631, a result seen for the first time ever in CAH patients - The gene therapy was well tolerated with no treatment- [...]

BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program

10/09/2024 - 22:45

- Receipt of RMAT Designation is based on preliminary clinical evidence from the CANaspire Phase 1/2 clinical trial, which showed functional improvements in all dosed patients indicating that BBP-812 has potential to [...]

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10/09/2024 - 22:40

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified [...]

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

10/09/2024 - 22:30

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

10/09/2024 - 22:30

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO) (“Telesis” or the “Company”), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through [...]

IRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas Growth “Big 8” Investor Conference

10/09/2024 - 22:30

WINTER SPRINGS, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today [...]

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference

10/09/2024 - 22:30

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products [...]

CooperCompanies Recognized as a Best Workplace for Innovators

10/09/2024 - 22:28

Leading global medical device company recognized for culture that drives innovation for customers and patients SAN RAMON, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) announced today that the [...]